Intrust Bank’s Coherus Oncology CHRS Stock Holding History

Intrust Bank’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,652	Closed	-$190K	–	343
2020 Q2	$190K	Sell	10,652 -1,111	-9%	-$18.8K	0.04%	316
2020 Q1	$191K	Buy	+11,763	New	+$217K	0.05%	301

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Intrust Bank's CHRS Position: Q3 2020 in Review

Intrust Bank sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 10,652 shares — an estimated $190K sold.

Intrust Bank first reported a position in CHRS in Q1 2020 and held it in 2 quarters. The position peaked at $191K in Q1 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

Intrust Bank reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
Intrust Bank sold 10,652 Coherus Oncology shares in Q3 2020, an estimated $190K.
Intrust Bank first reported a position in Coherus Oncology in Q1 2020 and held it in 2 quarters.
Intrust Bank's Coherus Oncology position peaked at $191K in Q1 2020.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on Intrust Bank's 13F filing for Q3 2020, filed 5 Nov 2020.